


In re: Dannhardt *et al.*
Appl. No.: 10/672,613
Filed: September 26, 2003
Atty. Dkt. No. 104035.269169
Page 2


Respectfully submitted,


Ryan W. Cagle
Registration No. 47,468
Attorney of Record

CUSTOMER NO. 00826
ALSTON & BIRD LLP
Bank of America Plaza
101 South Tryon Street, Suite 4000
Charlotte, NC 28280-4000
Tel Raleigh Office (919) 862-2200
Fax Raleigh Office (919) 862-2260

CERTIFICATION OF FACSIMILE TRANSMISSION

I hereby certify that this paper is being facsimile transmitted to the US Patent and Trademark Office at Fax No. (571) 273-8300 on the date shown below.


Rebecca Kerney

1/5/06
Date

This facsimile message and its contents are legally privileged and confidential information intended solely for the use of the addressee. If the reader of this message is not the intended recipient, you are hereby notified that any dissemination, distribution, copying or other use of this message and its contents is strictly prohibited. If you have received this telecopy in error, please notify us immediately by telephone and return the original message to us at the address shown below via the Postal Service. Thank You.

ALSTON & BIRD LLP

3201 Beechleaf Court, Suite 600
Raleigh, NC 27604-1062
919-862-2200
Fax: 919-862-2260

RECEIVED
CENTRAL FAX CENTER

JAN 05 2006

TELECOPY

PLEASE DELIVER AS SOON AS POSSIBLE

Date:

January 5, 2006

Recipient:

Technology Center 1626
Attn: Examiner Janet L. Coppins

Company:

U.S. Patent and Trademark Office

Fax Number:

(571) 273-8300

Voice Number:

(571) 272-0680

Sender:

Ryan W. Cagle, Esq.

Message:

Appl. No.: 10/672,613

Confirmation No.: 3699

Applicants: Dannhardt *et al.*

Filed: September 26, 2003

Art Unit: 1626

Examiner: J. Coppins

Title: 2-MERCAPTO-4,5-DIARYLIMIDAZOLE DERIVATIVES AND THE USE
THEREOF AS CYCLOOXYGENASE INHIBITORS

Documents Attached: Amendment Transmittal with Amendment (19 pages);
and Reference (9 pages)

Deposit Account: \$150.00 (Extra Claims fee)

Number of Pages: (including cover page) **29**

IF NOT RECEIVED PROPERLY, PLEASE NOTIFY US IMMEDIATELY AT (919) 862-2221.

USER CODE: KURNR	REQUESTED BY: Rebecca Kerney / <i>rk</i>
CLIENT/MATTER: 104035/269169	OPERATOR:

RTA01/2196346v1

Attorney's Docket No. 104035.269169

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED
CENTRAL FAX CENTER

In re: Dannhardt et al. Confirmation No.: 3699
 Appl. No.: 10/672,613 Group Art Unit: 1626
 Filed: September 26, 2003 Examiner: J. Coppins
 For: 2-MERCAPTO-4,5-DIARYLIMIDAZOLE DERIVATIVES AND THE USE
 THEREOF AS CYCLOOXYGENASE INHIBITORS

JAN 05 2006

Mail Stop Amendment
 Commissioner for Patents
 P.O. Box 1450
 Alexandria, VA 22313-1450

Transmitted herewith is an AMENDMENT in the above-identified patent application.

☐ Applicant claims small entity status. See 37 CFR §1.27.

The fee has been calculated as shown below:

(COL. 1)		(COL. 2)	(COL. 3)	SMALL ENTITY		OTHER THAN A SMALL ENTITY	
CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA	RATE	ADDIT. FEE	OR RATE	ADDIT. FEE
TOTAL	* 24	** 21	= 3	X 25=	\$0	X 50 =	\$150
INDEP	* 4	*** 4	= 0	X 100=	\$0	X 200=	\$0
<input type="checkbox"/> FIRST PRESENTATION OF MULTIPLE DEP. CLAIM				X 180=	\$0	+360=	\$0
				TOTAL ADD FEE \$0		OR TOTAL	\$150

* If the entry in Col. 1 is less than the entry in Col. 2, write "0" in Col. 3.

** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, write "20" in this space.

*** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, write "3" in this space.

The "Highest Number Previously Paid For" (Total or Independent) is the highest number found from the equivalent box in Col. 1 of a prior Amendment or the number of claims originally filed.

☒ Please charge my Deposit Account No. 16-0605 in the amount of \$150.00.

☐ A check in the amount \$_____ to cover the additional fee is enclosed.

☒ The Commissioner is hereby authorized to charge any deficiency in payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 16-0605.

☒ Any additional filing fees required under 37 CFR §1.16 for the presentation of extra claims.

☒ Any patent application processing fees under 37 CFR §1.17.

RTA01/2196345v1